BioCentury
ARTICLE | Clinical News

Phytopharm starts P54 Phase II

February 5, 2001 8:00 AM UTC

Phytopharm (LSE:PYM) began U.K. double-blind, placebo-controlled Phase II testing of its P54 cyclo-oxygenase 2, inducible nitric oxide synthase, in up to 36 patients with steroid-dependent inflammator...